Skip to main content

Advertisement

SpringerLink
Log in

Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry

  • Special Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

This is a prognostic report by the Japanese Breast Cancer Society on breast cancer extracted from the National Clinical Database-Breast Cancer Registry of Japan. Here, we present a summary of 457,878 breast cancer cases registered between 2004 and 2016. The median follow-up duration was 5.6 years. The median age at the start of treatment was 59 years (5–95%: 38–82 years) and increased from 57 years between 2004 and 2008 to 60 years between 2013 and 2016. The proportion of patients with Stage 0–II disease increased from 74.5% to 78.3%. The number of cases with estrogen and progesterone receptor positivity increased from 74.8% to 77.9% and 60.5% to 68.1%, respectively. Regarding (neo-)adjuvant chemotherapy, the taxane (T) or taxane-cyclophosphamide (C) regimen increased by 2.4% to 8.2%, but the (fluorouracil (F)) adriamycin (A)-C-T/(F) epirubicin (E)C-T and (F)AC/(F)EC regimens decreased by 18.6% to 15.2% and 13.5% to 5.0%, respectively. Regarding (neo-)adjuvant anti-human epidermal growth factor-2 (HER2)-targeted therapy, the use of trastuzumab increased from 4.6% to 10.5%. The rate of sentinel lymph node biopsy increased from 37.1% to 60.7%, while that of axillary dissection decreased from 54.5% to 22.6%. Improvements in disease-free and overall survival were observed in patients with HER2-positive breast cancer, but there was no apparent trend in patients with hormone receptor-positive, HER2-negative, or triple-negative breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data availability

Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so row data is not available.

References

  1. Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T, et al. Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer Tokyo Jpn. 2020;27:511–8.

    Article  Google Scholar 

  2. Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer Tokyo Jpn. 2020;27:803–9.

    Article  Google Scholar 

  3. Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, et al. Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018. Breast Cancer Tokyo Jpn. 2023;30:157–66.

    Article  Google Scholar 

  4. Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, et al. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;156:485–94.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016;160:163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Cancer Med. 2016;5:1328–40.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:480–7.

    Article  CAS  Google Scholar 

  8. Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat. 2019;178:647–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, et al. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: a study from the Japanese Breast Cancer Registry. Ann Surg Oncol. 2019;26:2475–85.

    Article  PubMed  Google Scholar 

  10. Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, et al. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. Breast Cancer Tokyo Jpn. 2020;27:85–91.

    Article  Google Scholar 

  11. Ogiya R, Niikura N, Kumamaru H, Takeuchi Y, Okamura T, Kinoshita T, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184:585–96.

    Article  PubMed  Google Scholar 

  12. Yamada A, Kumamaru H, Shimizu C, Taira N, Nakayama K, Miyashita M, et al. Systemic therapy and prognosis of older patients with stage II/III breast cancer: a large-scale analysis of the Japanese Breast Cancer Registry. Eur J Cancer Oxf Engl. 1990;2021(154):157–66.

    Google Scholar 

  13. Aihara T, Kumamaru H, Ishitobi M, Miyashita M, Miyata H, Tamura K, et al. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. Breast Cancer Res Treat. 2022;196:635–45.

    Article  CAS  PubMed  Google Scholar 

  14. Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer Tokyo Jpn. 2022;29:985–92.

    Article  Google Scholar 

  15. Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, et al. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer Tokyo Jpn. 2022;29:698–708.

    Article  Google Scholar 

  16. Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer Tokyo Jpn. 2022;29:1–8.

    Article  Google Scholar 

  17. Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, et al. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Res Treat. 2023;201:397–408.

    Article  CAS  PubMed  Google Scholar 

  18. Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer Tokyo Jpn. 2020;27:322–31.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank all the affiliated institutes participating in the Breast Cancer Registry of the JBCS for their efforts to register the patients’ data.

Funding

This work was funded by the Registration Committee of the Japanese Breast Cancer Society.

Author information

Authors and Affiliations

  1. Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Okayama, Japan

    Takayuki Iwamoto

  2. Department of Healthcare Quality Assessment, University of Tokyo, Tokyo, Japan

    Hiraku Kumamaru & Naoko Kinukawa

  3. Department of Breast Oncology, Tokai University School of Medicine, Kanagawa, Japan

    Naoki Niikura

  4. Department of Breast Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan

    Yasuaki Sagara

  5. Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Miyagi, Japan

    Minoru Miyashita

  6. Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Takaaki Konishi

  7. Radiation Therapy Department, Yokkaichi Municipal Hospital, Mie, Japan

    Naoko Sanuki

  8. Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, Tokyo, Japan

    Kenta Tanakura

  9. Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, Hyogo, Japan

    Masayuki Nagahashi

  10. Department of Surgery, Division of Breast Surgical Oncology, Showa University, Tokyo, Japan

    Naoki Hayashi

  11. Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan

    Masayuki Yoshida

  12. School of Nursing and Rehabilitation Sciences, Showa University, Tokyo, Japan

    Chie Watanabe

  13. Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

    Masakazu Toi

  14. Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan

    Shigehira Saji

Authors
  1. Takayuki Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiraku Kumamaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Niikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuaki Sagara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Minoru Miyashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takaaki Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoko Sanuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenta Tanakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Nagahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masayuki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chie Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Naoko Kinukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masakazu Toi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: TI, NN, YS and MM. Assembly of data: HK and NK. Manuscript writing: TI. Critical revision of the manuscript for important intellectual content: The Registration Committee of the JBCS (TI, NN, YS, MM, TK, NS, KT, MN, NH, MY, CW, and SS). Final approval of manuscript: All.

Corresponding author

Correspondence to Takayuki Iwamoto.

Ethics declarations

Conflict of interest

Grants or contracts from any entity: TI: Pfizer, NN: Chugai, Pfizer, Eisai, Mochida Institutional, Daiichi Sankyo and Novartis; TK: Pfizer Co. Ltd, Kanzawa Medical Research Foundation and Japan Kampo Medicines Manufacturers Association; MT: Chugai, Taiho, Takeda, JBCRG assoc., Pfizer, KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui, and Zene; SS: Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, and Daiichi Sankyo. Consulting fees: HK: EPS corporation; MY: Lilly Japan, and Roche Japan. Payment or honoraria for lectures: HK: Chugai Pharmaceuticals; NN: Chugai, Eli Lilly, MSD, Daiichi-Sankyo, AstraZeneca and Pfizer; YS: Pfizer, Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lily, Chugai, MSD and Nihon Kayaku; MM: Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Taiho, Daiichi Sankyo and Eisai; MN: Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Esai, Kyowa-Kirin, MSD, Myriad genetics and Denka; NH: Eli Lilly, Astrazeneca, taiho, Eizai, ExactScience,Daiichi-Sankyo, Novartis, Pfizer, and Chugai; MY: Agilent technologies, Chugai pharma, Ono Yakuhin, MSD, and Daiichi Sankyo; TM: Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, Daiichi-Sankyo, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore medical Japan, and Sysmex; SS: Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nipponkayaku. Participation on a Data Safety Monitoring Board or Advisory Board: MT: Daiichi-Sankyo, Eli Lilly and companies, Bertis, Terumo, and Kansai Medical Ne; SS: Chugai/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SS: JBCRG, JBCS, JSMO, and BIG.Other financial or non-financial interests: HK: Affiliation to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl; NK: Affiliation to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl; MT: British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, and Cancer Science.

Ethical approval

This study was approved by the Institutional Review Board (Permission number: 6200–00) at Kawasaki Medical School Hospital. This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwamoto, T., Kumamaru, H., Niikura, N. et al. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry. Breast Cancer 31, 185–194 (2024). https://doi.org/10.1007/s12282-024-01545-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-024-01545-x

Keywords

Search

Navigation